Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03487666
Title OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Georgetown University

triple-receptor negative breast cancer


Capecitabine + Nivolumab



Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
MedStar Georgetown University Hospital Recruiting Washington District of Columbia 20007 United States Details
MedStar Washington Hospital Center Recruiting Washington District of Columbia 20010 United States Details
University of Chicago Recruiting Chicago Illinois 60637 United States Details
John Theurer Cancer Center at Hackensack University Medical Center Recruiting Hackensack New Jersey 07601 United States Details
*Shaded cells indicate that there was no data available from for the field